This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (70)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Current Status and Future Prospects

Norman M. Kaplan, MD

JAMA. 1989;262(6):817-823.

Abstract
Calcium entry blockers will be increasingly used for the treatment of hypertension. The currently available calcium entry blockers are similar in antihypertensive efficacy but differ in their effects on the atrioventricular node and the degree of peripheral vasodilatory action. The new generation of dihydropyridine calcium entry blockers exhibits more specific vasodilatory actions with a less negative inotropic effect, which may affect their use in patients with congestive heart failure. The responsiveness to these drugs is little affected by race or age. Because of their mild natriuretic action, the concomitant use of dietary sodium restriction or diuretics may be less necessary. Short-term administration of calcium entry blockers preserves or improves renal function; however, their long-term effect has not been documented. Calcium entry blockers have not exhibited protection against coronary heart disease, but experimental evidence supports the continued search for cardioprotection. Calcium entry blockers are important drugs for the treatment of hypertension; the second generation may provide additional benefits because of its more specific pharmacologic actions.

(JAMA. 1989;262:817-823)

Author Affiliations
From the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

Footnotes
Reprint requests to the University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-8852 (Dr Kaplan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fluid Matters in Choosing Antihypertensive Therapy: A Hypothesis That the Data Speak Volumes
Blankfield
J Am Board Fam Med 2005;18:113-124.
ABSTRACT | FULL TEXT  

Hypertension and the Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2004;38:103-119.
ABSTRACT  

Mibefradil Improves {beta}-Adrenergic Responsiveness and Intracellular Ca2+ Handling in Hypertrophied Rat Myocardium
Min et al.
Exp. Biol. Med. 2002;227:336-344.
ABSTRACT | FULL TEXT  

Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967) : A New Generation of Calcium Antagonists?
Bernink et al.
Hypertension 1996;27:426-432.
ABSTRACT | FULL TEXT  

Calcium Antagonists in Elderly and Black Hypertensive Patients: Therapeutic Controversies
Zing et al.
Arch Intern Med 1991;151:2154-2162.
ABSTRACT  

Drug-Induced Fever due to Diltiazem
Dominguez and Hamill
Arch Intern Med 1991;151:1869-1870.
ABSTRACT  

Treatment of Hypertension in the Elderly
Tjoa and Kaplan
JAMA 1990;264:1015-1018.
ABSTRACT